A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer

LESSONS LEARNED. Ideally, patients should have access to an oral formulation of paclitaxel, as well as an intravenous formulation, to allow development of regimens exploring alternate schedules and to avoid reactions to Cremophor EL (BASF Corp., Ludwigshafen, Germany, https://www.basf.com). DHP107 i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Ryu, Min‐Hee, Ryoo, Baek‐Yeol, Kim, Tae Won, Kim, Sung Bae, Lim, Hyeong‐Seok, Bae, Kyun‐Seop, Park, Sook Ryun, Jo, Yeong‐Woo, Cho, Hyun Ju, Kang, Yoon‐Koo
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330712/
https://ncbi.nlm.nih.gov/pubmed/28196905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0273
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados